LASILACTONE

This brand name is authorized in United Kingdom

Active ingredients

The drug LASILACTONE contains a combination of these active pharmaceutical ingredients (APIs):

1 Spironolactone
UNII 27O7W4T232 - SPIRONOLACTONE

Spironolactone, as a competitive aldosterone antagonist, increases sodium excretion whilst reducing potassium loss at the distal renal tubule. It has a gradual and prolonged action.

Read about Spironolactone
2 Furosemide
UNII 7LXU5N7ZO5 - FUROSEMIDE

Furosemide inhibits active chloride transport in the thick ascending limb. Re-absorption of sodium, chloride from the nephron is reduced and a hypotonic or isotonic urine produced. The evidence from many experimental studies suggests that furosemide acts along the entire nephron with the exception of the distal exchange site.

Read about Furosemide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C03EB01 Furosemide and potassium-sparing agents C Cardiovascular system → C03 Diuretics → C03E Diuretics and potassium-sparing agents in combination → C03EB High-ceiling diuretics and potassium-sparing agents
Discover more medicines within C03EB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 147645, 36459

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.